{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:59:40Z","timestamp":1788303580713,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"F.R.S.-FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Fund for Scientific Research"},{"name":"Excellence of Science","award":["F 5\/4\/150\/5"],"award-info":[{"award-number":["F 5\/4\/150\/5"]}]},{"name":"Excellence of Science","award":["FC 54372"],"award-info":[{"award-number":["FC 54372"]}]},{"name":"Excellence of Science","award":["1.A.094.21F"],"award-info":[{"award-number":["1.A.094.21F"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mepolizumab, an anti-interleukin-5 antibody, has been proven a safe and effective glucocorticoid (GC)-sparing drug for many patients with nonclonal hypereosinophilic syndrome (HES) and is now approved in many countries. It remains unclear, however, which patients are most likely to benefit from therapy and whether the currently approved dosing regimen is appropriate for all. This observational retrospective study included all patients with HES who were enrolled in the MHE104317 compassionate use program (CUP) in our center. Patient and disease characteristics, mepolizumab dosing, and both clinical and hematological responses to treatment were collected from medical files. Treatment responses and mepolizumab dosing requirements were analyzed according to disease characteristics. Eighteen patients with HES were enrolled in the CUP, of whom nine are still on treatment. The median duration of exposure to mepolizumab was 45 mo (maximum 18 yr). A lower number of affected organs, requirement for GC dosing \u226410 mg prednisone-equivalent, and single-organ HES were associated with a higher likelihood of complete response. Lymphocytic variant HES (L-HES) was less treatment-responsive, leading to withdrawal and\/or requiring higher mepolizumab dosing to achieve some degree of disease control. In contrast, all patients with single-organ disease had a complete response that could often be maintained despite increasing between-dose intervals. Few potentially treatment-related adverse events were observed despite prolonged exposure. This study confirms the efficacy and safety of mepolizumab in HES, although patients with L-HES rarely experience a complete response. In contrast, patients with single-organ disease affecting the lungs are often super-responders, and decreasing mepolizumab dosing may be attempted.<\/jats:p>","DOI":"10.1093\/jleuko\/qiae152","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T13:23:11Z","timestamp":1720272191000},"page":"1021-1032","source":"Crossref","is-referenced-by-count":6,"title":["Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program"],"prefix":"10.1093","volume":"116","author":[{"given":"Gauthier","family":"Coussement","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles , 808 Route de Lennik, 1070 Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Catherine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles , 808 Route de Lennik, 1070 Brussels ,","place":["Belgium"]},{"name":"Institute for Medical Immunology, Universit\u00e9 Libre de Bruxelles , 8 Rue Adrienne Bolland, 6041 Gosselies ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles , 808 Route de Lennik, 1070 Brussels ,","place":["Belgium"]},{"name":"Institute for Medical Immunology, Universit\u00e9 Libre de Bruxelles , 8 Rue Adrienne Bolland, 6041 Gosselies ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"issue":"1","key":"2024110323514149900_qiae152-B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"issue":"3","key":"2024110323514149900_qiae152-B2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"2024110323514149900_qiae152-B3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"25","key":"2024110323514149900_qiae152-B4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJM198406213102501","article-title":"Episodic angioedema associated with eosinophilia","volume":"310","author":"Gleich","year":"1984","journal-title":"N Engl J Med"},{"issue":"6","key":"2024110323514149900_qiae152-B5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2024110323514149900_qiae152-B6","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"20","key":"2024110323514149900_qiae152-B7","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2024110323514149900_qiae152-B8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2024110323514149900_qiae152-B9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.V76.2.285.285","article-title":"Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia","volume":"76","author":"Meeker","year":"1990","journal-title":"Blood"},{"issue":"4","key":"2024110323514149900_qiae152-B10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2024110323514149900_qiae152-B11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"2024110323514149900_qiae152-B12","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2024110323514149900_qiae152-B13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2024110323514149900_qiae152-B14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.alit.2021.11.003","article-title":"Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis","volume":"71","author":"Anai","year":"2022","journal-title":"Allergol Int"},{"key":"2024110323514149900_qiae152-B15","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3389\/fimmu.2018.01198","article-title":"Efficacy and safety of mepolizumab (anti-interleukin-5) treatment in Gleich's syndrome","volume":"9","author":"Matucci","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2024110323514149900_qiae152-B16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2023.11.002","article-title":"Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia","volume":"153","author":"Khoury","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2024110323514149900_qiae152-B17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3324\/haematol.2013.091264","article-title":"Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder","volume":"100","author":"Khoury","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2024110323514149900_qiae152-B18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"issue":"6","key":"2024110323514149900_qiae152-B19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.anai.2021.02.016","article-title":"Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab","volume":"126","author":"Ricketti","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"2024110323514149900_qiae152-B20","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jaip.2022.02.037","article-title":"Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease","volume":"10","author":"Kuang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"2024110323514149900_qiae152-B21","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/1346-8138.16604","article-title":"Gleich syndrome and eosinophilic fasciitis overlap successfully treated with mepolizumab","volume":"49","author":"Gambichler","year":"2022","journal-title":"J Dermatol"},{"issue":"8","key":"2024110323514149900_qiae152-B22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.55563\/clinexprheumatol\/j7gexb","article-title":"Mepolizumab for refractory eosinophilic fasciitis: a retrospective analysis from two tertiary care centres","volume":"41","author":"Sanchez-Melendez","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2024110323514149900_qiae152-B23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"14","key":"2024110323514149900_qiae152-B24","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2024110323514149900_qiae152-B25","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1016\/j.jaad.2019.02.001","article-title":"Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich syndrome): frequency, clinical implication, and prognosis","volume":"88","author":"Abisror","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2024110323514149900_qiae152-B26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jaip.2022.12.022","article-title":"Targeting IL-5\/5R for the treatment of idiopathic chronic eosinophilic pneumonia","volume":"11","author":"Delcros","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2024110323514149900_qiae152-B27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"2024110323514149900_qiae152-B28","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2024110323514149900_qiae152-B29","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2014","journal-title":"Leuk lymphoma"},{"issue":"2","key":"2024110323514149900_qiae152-B30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2024110323514149900_qiae152-B31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1479-5876-11-112","article-title":"Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells","volume":"11","author":"Harfi","year":"2013","journal-title":"J Transl Med"},{"issue":"10","key":"2024110323514149900_qiae152-B32","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"26","key":"2024110323514149900_qiae152-B33","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.12998\/wjcc.v11.i26.6154","article-title":"Mepolizumab induced palmoplantar psoriasis: a case report","volume":"11","author":"Artosi","year":"2023","journal-title":"World J Clin Cases"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jleukbio\/advance-article-pdf\/doi\/10.1093\/jleuko\/qiae152\/58514592\/qiae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/116\/5\/1021\/60213196\/qiae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/116\/5\/1021\/60213196\/qiae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T23:51:53Z","timestamp":1730677913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/116\/5\/1021\/7708691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7,6]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jleuko\/qiae152","relation":{},"ISSN":["1938-3673"],"issn-type":[{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,6]]}}}